Apogee Therapeutics Inc [APGE] stock is trading at $37.14, down -4.48%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The APGE shares have gain 2.00% over the last week, with a monthly amount drifted -11.28%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apogee Therapeutics Inc [NASDAQ: APGE] stock has seen the most recent analyst activity on July 07, 2025, when BTIG Research reiterated its Buy rating and also boosted its price target to $115 from $100. Previously, Citigroup started tracking the stock with Buy rating on March 13, 2025, and set its price target to $95. On November 25, 2024, Canaccord Genuity initiated with a Buy rating and assigned a price target of $89 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $80 on May 10, 2024. BTIG Research initiated its recommendation with a Buy and recommended $43 as its price target on December 20, 2023. Wedbush started tracking with a Outperform rating for this stock on August 08, 2023, and assigned it a price target of $40. In a note dated August 08, 2023, TD Cowen initiated an Outperform rating.
Apogee Therapeutics Inc [APGE] stock has fluctuated between $26.20 and $63.50 over the past year. Currently, Wall Street analysts expect the stock to reach $95 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $37.14 at the most recent close of the market. An investor can expect a potential return of 155.79% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.19 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.30 points at the first support level, and at 35.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.72, and for the 2nd resistance point, it is at 40.31.
Ratios To Look Out For
For context, Apogee Therapeutics Inc’s Current Ratio is 15.82. Further, the Quick Ratio stands at 15.82, while the Cash Ratio is 3.24.
Transactions by insiders
Recent insider trading involved Dambkowski Carl, Chief Medical Officer, that happened on Jul 02 ’25 when 10090.0 shares were sold. Officer, CARL DAMBKOWSKI completed a deal on Jul 02 ’25 to buy 22345.0 shares. Meanwhile, Chief Medical Officer Dambkowski Carl sold 2725.0 shares on Jun 04 ’25.
